Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07414134 · ClinicalTrials.gov registry record
Exacerbations and Real-World Outcomes Among Patients With Chronic Obstructive Pulmonary Disease Following Severe Exacerbation
A clinical trial of Chronic Obstructive Pulmonary Disease, sponsored by AstraZeneca.
- Completed
- Registry status
- 3,598
- Enrollment target
- 1
- Study location
NCT07414134: Completed study of Chronic Obstructive Pulmonary Disease, sponsored by AstraZeneca.
NCT07414134 is a study of Chronic Obstructive Pulmonary Disease that has completed, run by AstraZeneca. The registered enrollment target is 3,598 participants, above the 1,712-participant average among 86 other Chronic Obstructive Pulmonary Disease trials with a reported enrollment target (110% higher). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT07414134, a study of Chronic Obstructive Pulmonary Disease, has completed, sponsored by AstraZeneca.
- COMPLETED
- Registry status
- 3,598 participants
- Enrollment target
- 1
- Study location
Study Summary
This real-world retrospective study will use de-identified administrative claims data and will examine patients with a diagnosis of COPD who have experienced a qualifying severe disease exacerbation and received subsequent treatment with BGF. Agreed COPD patient data from the Inovalon MORE2 Registry® and Centers for Medicare \& Medicaid Services (CMS) 100% Medicare Fee for Service (FFS) database spanning from January 1, 2021 to the most recently available data (September 30th, 2024 for the MORE2 database, and December 31st, 2023 for the Medicare FFS database) will be used for this analysis. All patients will be required to present at least one prescription claim for BGF. Patients will also be required to show evidence of a qualifying severe COPD exacerbation event during the 180-day period preceding initiation of BGF. Index date will be set as the date of discharge from the qualifying severe exacerbation event.
Primary Outcome
Annualized rates of COPD exacerbation events observed from index date (qualifying exacerbation event) through study completion (or until end of data availability
Conditions Studied
Interventions
- DRUG BGF- BUDESONIDE/GLYCOPYRRONIUM/FORMOTEROL
Study Locations (1)
Maryland
- AstraZeneca - Gaithersburg
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 3,598 participants |
| Start Date | 2025-10-31 |
| Est. Completion | 2025-11-28 |
What the finished NCT07414134 record still lists
NCT07414134 is an observational study that tracks outcomes without assigning an intervention. Its 3,598 participants enrollment target places it among the larger protocols in the corpus, above the 1,712-participant average among 86 other Chronic Obstructive Pulmonary Disease trials with a reported enrollment target (110% higher).
The record links to 1 condition, with Chronic Obstructive Pulmonary Disease appearing as the primary indexed condition, and to 1 intervention - of which BGF- BUDESONIDE/GLYCOPYRRONIUM/FORMOTEROL is the first listed.
NCT07414134 reports a single indexed study location in Maryland.
Frequently Asked Questions
What is clinical trial NCT07414134 about?
NCT07414134 is a clinical study titled "Exacerbations and Real-World Outcomes Among Patients With Chronic Obstructive Pulmonary Disease Following Severe Exacerbation". This real-world retrospective study will use de-identified administrative claims data and will examine patients with a diagnosis of COPD who have experienced a qualifying severe disease exacerbation and received subsequent treatment with BGF. Agreed COPD patient data from the Inovalon MORE2 Registry...
What is the current status of trial NCT07414134?
This trial is currently completed. The enrollment target is 3,598 participants. The study started on 2025-10-31. Estimated completion is 2025-11-28.
What conditions does trial NCT07414134 study?
This clinical trial studies the following conditions: Chronic Obstructive Pulmonary Disease.
What interventions are being tested in trial NCT07414134?
The interventions under investigation include: BGF- BUDESONIDE/GLYCOPYRRONIUM/FORMOTEROL (DRUG).
Who is sponsoring clinical trial NCT07414134?
This trial is sponsored by AstraZeneca, which has 1,285 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT07414134 being conducted?
This trial has 1 study location across Maryland. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Chronic Obstructive Pulmonary Disease
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT07414134's enrollment target sits among peer trials
3,598 4th of 86 higher than 83 of 86 other Chronic Obstructive Pulmonary Disease trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Chronic Obstructive Pulmonary Disease trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Mindful Steps 2.0: Promoting Physical Activity in Patients With COPD and HF
RECRUITING · NA
-
Boston Early-Onset Chronic Obstructive Pulmonary Disease (COPD) Study
RECRUITING
-
Evaluating the Safety and Efficacy of dNerva Lung Denervation System in Patients With COPD
RECRUITING · NA
-
A Study to Assess the Efficacy and Safety of Verekitug in Participants With COPD
RECRUITING · Phase 2
-
The Cardiovascular Consequences of Sleep Apnea Plus COPD (Overlap Syndrome)
RECRUITING · Phase 2
-
COPD Care Pathway Among Patients With Cancer
RECRUITING
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT06088498 · 3,600 participants · Phase 2
App for Reducing Cravings to Smoke
- NCT06501118 · 3,600 participants · NA
Optimizing Care in Critically Ill at UCHealth by Liberalizing the Target O2 in Mechanically-ventilated ICU Patients
- NCT06919419 · 3,600 participants · NA
HOTSPOT Study: Implement and Evaluate the PrEP (Pre-exposure Prophylaxis) Implementation Strategy
- NCT07091032 · 3,600 participants · NA
Building Connections
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI